Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
10.99
-0.21 (-1.87%)
Nov 13, 2026, 4:00 PM EST - Market closed
Enanta Pharmaceuticals Revenue
Enanta Pharmaceuticals had revenue of $14.36M in the quarter ending June 30, 2026, a decrease of -21.60%. This brings the company's total for the last twelve months to $65.26M, up 0.70% year-over-year. In the fiscal year ending September 30, 2025, Enanta Pharmaceuticals had annual revenue of $65.32M, down -3.42%. That makes Enanta Pharmaceuticals the 25,971st largest company in the world by revenue and 3,582nd in the United States.
Revenue (ttm)
$65.26M
Revenue Growth
+0.70%
P/S Ratio
4.90
Revenue / Employee
$543,817
Employees
120
Market Cap
320.09M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 65.32M | -2.31M | -3.42% |
| Sep 30, 2024 | 67.64M | -11.57M | -14.61% |
| Sep 30, 2023 | 79.20M | -6.96M | -8.07% |
| Sep 30, 2022 | 86.16M | -10.91M | -11.24% |
| Sep 30, 2021 | 97.07M | -25.40M | -20.74% |
| Sep 30, 2020 | 122.47M | -82.72M | -40.31% |
| Sep 30, 2019 | 205.20M | -1.43M | -0.69% |
| Sep 30, 2018 | 206.63M | 103.81M | 100.97% |
| Sep 30, 2017 | 102.81M | 14.55M | 16.48% |
| Sep 30, 2016 | 88.27M | -72.61M | -45.13% |
| Sep 30, 2015 | 160.88M | 113.14M | 236.98% |
| Sep 30, 2014 | 47.74M | 15.69M | 48.94% |
| Sep 30, 2013 | 32.05M | -9.65M | -23.15% |
| Sep 30, 2012 | 41.71M | -176.00K | -0.42% |
| Sep 30, 2011 | 41.88M | 19.12M | 83.99% |
| Sep 30, 2010 | 22.76M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Autolus Therapeutics | 137.43M |
| Editas Medicine | 49.83M |
| Scribe Therapeutics | 33.30M |
| X4 Pharmaceuticals | 16.96M |
| Altimmune | 26.00K |
ENTA News
- 9 days ago - Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences - Business Wire
- 16 days ago - Enanta announces retirement of CEO Luly, appoints Kieffer as COO - TheFly
- 16 days ago - Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D. - Business Wire
- 18 days ago - Enanta announces first patient dosed in Resolve Phase 2b/3 trial - TheFly
- 18 days ago - Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) - Business Wire
- 4 weeks ago - Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026 - Business Wire
- 1 month ago - Enanta Pharmaceuticals Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 1 month ago - Enanta Pharmaceuticals Transcript: 2026 Global Healthcare Conference - Transcripts